The Daily PulseHealth
One‑third of antidepressant users face treatment‑resistant depression, prompting alternative brain‑stimulation therapies
Reported by Imran Qureshi (Staff Writer) · The Hindu - Health ·
Confirmed by a second source: Google News - UK Health
Photo: Wikimedia CommonsAbout 30% of people with major depressive disorder who have tried antidepressants develop treatment‑resistant depression, meaning they have not improved after adequate trials. Treatment‑resistant depression is defined when a patient fails to respond to at least two different antidepressants taken at proper doses for six to eight weeks each. Experts warn that missed doses, low doses, drug interactions or co‑existing medical problems can mimic resistance. Priya, a 32‑year‑old from Kerala, saw her symptoms persist despite weeks of medication and now undergoes repetitive transcranial magnetic stimulation (rTMS), a non‑invasive method that uses magnetic pulses to target mood‑regulating brain areas. Her case illustrates the challenge doctors face in deciding when to move beyond pills. Consultant psychiatrist Venkatesh Madankumar of Prashanth Hospitals, Chennai, says doctors must first rule out factors such as poor adherence, side effects, alternative diagnoses like bipolar disorder, substance use, psychosis or PTSD before labeling a case as resistant. Vivian Kapil of SRM Prime Hospital adds that physical health issues such as anaemia or thyroid disorders may also affect response. When standard antidepressants fail, clinicians may increase the dose, switch drugs, add another medication, or introduce psychotherapy such as cognitive‑behavioural therapy. In more severe cases, ketamine or esketamine, electroconvulsive therapy (ECT), or newer options like rTMS or vagus‑nerve stimulation are considered, each with specific risks and monitoring needs. rTMS does not require anaesthesia, is done while the patient is awake, and may cause scalp discomfort or rare seizures; its cost and need for multiple weekly sessions limit access in many centres.
Context
Treatment‑resistant depression affects a sizable share of patients and pushes the health system to offer advanced brain‑stimulation therapies, highlighting the need for early, accurate assessment and broader availability of options.
ExplainerWhy this matters
What Happened
An estimated 30% of patients with major depressive disorder do not improve after trying at least two antidepressants for six to eight weeks each, a condition doctors label as treatment‑resistant depression. The article cites Priya, a 32‑year‑old from Kerala, who moved to repetitive transcranial magnetic stimulation (rTMS) after standard medicines failed.
Why It Matters
The high share of resistant cases means many people remain symptomatic, risking work loss, relationship strain and poorer health. Recognising true resistance versus factors like missed doses or other illnesses is crucial, as it guides doctors toward safer, faster‑acting options such as ketamine, electroconvulsive therapy or newer brain‑stimulation methods. These alternatives can reduce suicide risk and improve quality of life, but they require careful monitoring and may be costly or unavailable in some centres.
What Happens Next
Clinicians will continue to screen for adherence issues, medical comorbidities and alternative diagnoses before confirming resistance. As more hospitals adopt rTMS and related technologies, access may widen, though cost and the need for multiple sessions will remain barriers. Ongoing research and policy support will determine how quickly these advanced therapies become part of routine depression care.
More in Health
HealthUnconfirmed — Reported by one source so farWorth knowing
Centenary celebrations of Dr K.V. Thiruvengadam launch with emphasis on bedside care.
Reported by Neha Sharma (Staff Writer) · The Hindu - Health ·
